News

Clinical Trials for Psilocybin Indicate No Adverse Effects

Clinical Trials for Psilocybin Indicate No Adverse Effects

A phase I clinical trial conducted by researchers at King's College London and mental healthcare company Compass Pathways, indicates that the drug psilocybin has no adverse effects. Psilocybin induces hallucinogenic symptoms, which may be advantageous for some suffering from chronic depression. Yourway is able to transport even controlled substances across our global network.

Back to Index
Media

Upcoming Event

Clinical Trial Supply Europe

March 11-12, 2020
Madrid, Spain
Booth #54

Media

Articles

Agility and Flexibility in a Company That Provides Both Courier and Clinical Packaging Services